不同年龄患者采用孕激素促排卵方案或GnRH拮抗剂方案整倍体率的比较
研究纳入418例接受PGT-A的患者(440个周期),按女性年龄<35岁与≥35岁分组,比较PPOS与GnRH-a方案的整倍体情况。≥35岁组中,PPOS方案的整倍体囊胚率显著高于GnRH-a方案,嵌合体率显著更低;<35岁组两种方案无显著差异。卵巢刺激方案与持续妊娠率无关联。
要点
- ≥35岁组PPOS方案每MⅡ卵母细胞整倍体囊胚率15.48%,高于GnRH-a方案的10.47%(P<0.05)。
- ≥35岁组PPOS方案每活检囊胚整倍体率54.94%,高于GnRH-a方案的40.88%(P<0.05)。
- ≥35岁组PPOS方案每活检囊胚嵌合体率8.64%,低于GnRH-a方案的23.36%(P<0.001)。
核心结论
- PPOS适用于接受PGT-A的患者,尤其是高龄患者,因为PPOS方案可获得更高的整倍体囊胚率。
研究设计与样本
- 研究纳入接受PGT-A的患者418例、共440个周期,按女性年龄分为<35岁和≥35岁两组。
- PPOS组:<35岁131例(137个周期),≥35岁72例(80个周期)。
- GnRH-a组:<35岁149例(152个周期),≥35岁66例(71个周期)。
主要发现
- ≥35岁组中,PPOS方案每MⅡ卵母细胞整倍体囊胚率为15.48%,GnRH-a方案为10.47%(P<0.05)。
- ≥35岁组中,PPOS方案每活检囊胚整倍体率为54.94%,GnRH-a方案为40.88%(P<0.05)。
- ≥35岁组中,PPOS方案每活检囊胚嵌合体率为8.64%,GnRH-a方案为23.36%(P<0.001)。
- <35岁组中,两种方案间未见显著差异(P>0.05)。
- 所有参与者中,女性年龄与整倍体率呈显著负相关(β -0.109,95%CI -0.183至-0.035,P=0.004);≥35岁组中,GnRH-a方案(参照:PPOS)与整倍体率相关(β -0.126,95%CI -0.248至-0.004,P=0.042)。
关键数值与推荐
- ≥35岁组:PPOS方案每MⅡ卵母细胞整倍体囊胚率15.48% vs GnRH-a方案10.47%(P<0.05)。
- ≥35岁组:PPOS方案每活检囊胚整倍体率54.94% vs GnRH-a方案40.88%(P<0.05)。
- ≥35岁组:PPOS方案每活检囊胚嵌合体率8.64% vs GnRH-a方案23.36%(P<0.001)。
- 多因素logistic回归显示,卵巢刺激方案与持续妊娠率无关联(OR 0.652,95%CI 0.358至1.177;P=0.14)。
临床怎么用
- 作者认为,PPOS适用于接受PGT-A的患者,尤其是高龄患者,因为PPOS方案可获得更高的整倍体囊胚率。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Does euploidy status differ among patients of different ages treated with progestin-primed ovarian stimulation (PPOS) or gonadotrophin releasing hormone antagonist (GnRH-a) protocols? DESIGN: Patients undergoing PGT-A (n = 418; 440 cycles) were enrolled and grouped according to female age (<35 years and ≥35 years). Protocols were as follows: PPOS: <35 years (n = 131; 137 cycles); ≥35 years (n = 72; 80 cycles); GnRH-a: <35 years (n = 149; 152 cycles); ≥35 years (n = 66; 71 cycles). RESULTS: For cycles treated with PPOS in the older group, rates of euploid blastocyst per metaphase Ⅱ oocyte (15.48% versus 10.47%) and per biopsied blastocyst (54.94% versus 40.88%) were significantly higher than those treated with GnRH-a (P < 0.05). The mosaic rate per biopsied blastocyst was significantly lower for cycles treated with PPOS than cycles treated with GnRH-a (8.64% versus 23.36%) (P < 0.001). In the younger group, no significant difference was found between treatments (P > 0.05). In older and younger groups, the drug to inhibit LH surge was cheaper for cycles treated with PPOS compared with GnRH-a (P < 0.001). Generalized estimation equations based on binomial distribution female age and euploidy rate was significantly negatively correlated for all participants (β -0.109, 95% CI -0.183 to -0.035, P = 0.004), and between GnRH-a protocol (reference: PPOS) and the euploidy rate in the older group (β -0.126, 95% CI -0.248 to -0.004, P = 0.042). Multiple logistic regression indicated that ovarian stimulation protocol was not associated with ongoing pregnancy rate (OR 0.652, 95% CI 0.358 to 1.177; P = 0.14). CONCLUSIONS: PPOS is suitable for patients undergoing PGT-A, particularly older patients for the higher euploid blastocyst rate attained by PPOS protocol.
引用
- Wan L, Chen F, Xiong D, et al. Comparison of aneuploidy for patients of different ages treated with progestin-primed ovarian stimulation or GnRH antagonist protocols. Reprod Biomed Online. 2024. PMID: 39213984. doi:10.1016/j.rbmo.2024.104349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。